Nephrology News
Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes
Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/